EACA treatment of mice with BCR-ABL1+ B-ALL resulted in significantly higher fibronectin levels as seen in ANXA2-deficient mice (Fig. 7C; Supplementary Fig. 18J). Here, ANXA2 is linked to precursor B-cell acute lymphoblastic leukemia.